Q32 Bio presented positive Phase 1 clinical trial results for ADX-097 at the American Society of Nephrology Kidney Week 2024 on October 26, 2024. The data highlighted that ADX-097 was generally well-tolerated and exhibited desirable pharmacokinetic and pharmacodynamic properties in healthy volunteers. These results support the continued clinical advancement of ADX-097 and inform Phase 2 dose selection.
ADX-097 is Q32 Bio's lead product candidate from its tissue-targeted complement inhibitor platform, designed to treat renal diseases associated with increased complement activation. The company aims for ADX-097 to achieve relevant complement inhibition directly in the tissue while minimizing systemic complement blockade. This approach seeks to address limitations of current systemic therapies, such as infection risk and the need for high drug doses.
Q32 Bio is currently evaluating ADX-097 in an open-label Phase 2 renal basket clinical trial and plans to evaluate it in a Phase 2 clinical trial in ANCA-Associated Vasculitis (AAV). The positive Phase 1 data reinforces the potential of this novel and differentiated approach to inhibiting the complement system. This progress is crucial for the company's innate immunity program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.